ZLB Behring completed its purchase of CytoGam, which is used to prevent infections in organ transplant patients, and related assets from MedImmune Inc. on Monday.
Under the terms of the deal, ZLB of King of Prussia, Pa., will pay MedImmune of Gaithersburg, Md., $120 million in cash, $70 million of which is subject to achievement of sales milestones.
The related assets that are part of the acquisition include trademarks, manufacturing contracts and government authorizations associated with the product.
CytoGam, an intravenous immunoglobulin made from human plasma, is enriched in antibodies that target cytomegalovirus -- the most common cause of life-threatening infection occurring in solid organ transplants.
ZLB, which specializes in plasma protein biotherapeutics, is a subsidiary of CSL Ltd. of Melbourne, Australia.
(NASDAQ:MEDI trading is basically unchanged today. I can post the CMV viral data and infection if there is interest.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment